Impurity Control in Pharmaceutical Intermediates: Insights from a Production Perspective

In the pharmaceutical industry, many quality issues do not originate at the API (Active Pharmaceutical Ingredient) stage, but rather at the earlier, often overlooked stage of Pharmaceutical Intermediates.

My particular focus on “impurity control” stems not from its fancy terminology, but from decades of production experience revealing that 80% of factors affecting final API quality can be prevented at the intermediate stage.

This article is grounded in practical experience, eschewing abstract theory to share key insights distilled from real-world manufacturing. We’ll discuss pitfalls encountered in impurity control, patterns observed, and actionable solutions.

Why Start Impurity Control at the Intermediate Stage?

If API quality is likened to a building’s stability, then pharmaceutical intermediates form its foundation.

Many companies focus quality control at the API end, but our long-term project experience reveals:

• Impurities in the API are often carryovers from the intermediate stage
• Once impurities become structurally fixed in intermediates, complete removal via subsequent purification is nearly impossible
• Downstream customers assess process maturity based on the impurity profile of intermediates

In other words, leading API manufacturers prioritize quality control starting from intermediates.

Where Do Intermediate Impurities Originate? (Four Identified Sources)

Based on observations across diverse projects, intermediate impurities stem from four primary categories:

① Raw Material Impurities: Raw material quality determines the initial impurity baseline

Example: Aromatic amine raw materials often contain low-level byproducts. Without prior assessment, subsequent condensation and addition reactions amplify these impurities.

② Reaction byproducts: Influenced by temperature/ratio/pH

Our most typical example:

In a hydrogenation process, merely adjusting the heating rate by 2–3°C resulted in a 20% difference in byproduct ratio.

Such impurities are often difficult to predict through testing alone and require practical batch experience.

③ Residual solvents and catalysts: Easily overlooked issues

Many testing methods focus more on structure-related impurities, while residual solvents (e.g., DMF) and catalysts (Pt/C, Pd/C) are more likely to be neglected.

Yet these are often the points of greatest concern to customers.

④ Human and Process Environmental Factors

Includes:

• Batch-to-batch variations
• Inadequate equipment cleaning
• Dead-end residue in reactors

These issues lie beyond SOPs (Standard Operating Procedures) and cannot be resolved solely through documentation; they require iterative experience.

Five “Impurity Control Methods” Validated in Our Projects

These methods have been repeatedly validated across dozens of intermediate projects and are shared for reference.

① Establish an “Impurity Baseline”

Many companies rush to optimize processes from the outset, but we recommend first answering this question:

“What impurities consistently appear under the most basic process conditions? Where do they originate?”

The value of an impurity baseline lies in:

• Clarifying optimization objectives
• Demonstrating your understanding of the process to clients
• Providing a documented basis for subsequent process adjustments

② Employ Cross-Verification with Multiple Detection Methods, Not Just HPLC

HPLC provides only one-dimensional impurity information. In actual projects, we utilize:

• HPLC (Quantitative)
• LC–MS (Structural Identification)
• GC (Solvent Impurities)
• ICP-MS (Catalyst Residues)

Especially LC–MS, which enables earlier impurity structural identification and facilitates root cause analysis.

③ Subject PV batches to “extreme condition challenges”

During PV (Process Validation), we deliberately subject batches to extreme conditions, such as:

• pH fluctuations of ±0.2
• Temperature variations of ±3°C
• Raw material content reduction of 1–2%

The rationale is straightforward:

Real production never occurs under “perfect conditions.” Clients will ask: “Can your impurity control remain stable under extreme conditions?”

④ Keep IPCs minimal but precise

We often see companies adding excessive IPC metrics to appear “stricter,” which actually creates operational chaos.

Our experience-based principles:

✔ Keep IPCs lean and focused (2–3 is sufficient)

✔ Each IPC must significantly influence impurity trends

✔ Test only critical points—not “all parameters”

Example: For condensation reactions, prioritize:

• Mid-reaction HPLC monitoring of main/side peak ratio
• Endpoint pH
• Endpoint residual raw material content

This approach enhances control effectiveness and consistency.

⑤ Establish a “Batch-to-Batch Impurity Tracking Model”

We create trend charts for critical impurity data across each batch, focusing on three points:

1. Whether impurities show fluctuating increases
2. Whether deviations occur during seasonal changes (temperature significantly impacts reactions)
3. Whether deviations correlate with specific operators or equipment conditions

This allows us to predict potential quality risks 1–2 months in advance.

Key Considerations for Procurement or Downstream API Companies

To enhance practicality, here’s an evaluation method we often share with clients:

When assessing an intermediate supplier, these questions are critical:

1. Can they clearly explain the sources of major impurities?
2. Do they maintain Process Verification (PV) batch records?
3. Can they provide consistent impurity profiles across three batches?
4. Have they conducted stress testing under extreme conditions?
5. Have they established impurity trend charts?

If the supplier cannot answer these questions, their impurity control capabilities are likely limited.

Conclusion: Impurity Control Is Not Documentation, but Accumulated Experience

Impurity control for pharmaceutical intermediates cannot be resolved with a simple statement like “We strictly adhere to GMP.”

It requires:

• A thorough understanding of reaction mechanisms
• Long-term observation of process trends
• Sensitivity to adverse reactions in each batch
• Familiarity with equipment, environment, and personnel
• Proactive preparation for customer requirements

More importantly, it must rely on real-world experience.

We hope this article provides you with a deeper, practical understanding of “impurity control in pharmaceutical intermediates.” If you encounter difficulties with impurities in a specific intermediate, we can also assist in analyzing the process mechanisms.

For technical exchanges and sample services, please contact Tianming Pharmaceutical Group’s online representatives:
Email: sunqian0123@gmail.com/WhatsApp: +8617663713557